Clinical Trials
LTO Network and Sphereon Partner With Triall for World’s First Application of Blockchain Technology to COVID-19 Clinical Trials
Dutch blockchain companies LTO Network and Sphereon have partnered with Triall, experts in the realm of blockchain and clinical research, to deliver the first COVID-19...
Clinical Trials
Reliance obtains DCGI approval to conduct Phase I Covid-19 vaccine trial
Reliance Life Sciences has obtained approval from the Drugs Controller General of India (DCGI) to carry out a Phase I clinical trial of its Covid-19...
Clinical Trials
Sorrento begin patient enrollment in phase 2 study of COVI-MSC to treat Covid-19 associated ARD in ICU patients
Sorrento Therapeutics, Inc. announced the start of enrollment in its Phase 2 efficacy study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC™) for patients suffering...
Clinical Trials
NRx’s Zyesami lowers respiratory distress in Phase IIb/III Covid-19 trial
NRx Pharmaceuticals has reported additional data from Phase IIb/III clinical trial where its drug, Zyesami (aviptadil), offered a rise in blood oxygen within a day...
Clinical Trials
Curevac’s CV2CoV Demonstrates Improved Immune Response And Protection In Preclinical Study
CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, and GSK announced the publication of preclinical...
Clinical Trials
Valneva Initiates Further Phase 3 Clinical Trial for its COVID-19 Vaccine Candidate
Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, announced the...
Clinical Trials
AzurRx BioPharma Adds New Clinical Trial Sites in Ukraine for Phase 2 RESERVOIR of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
AzurRx BioPharma, Inc., a company specializing in the development of targeted non-systemic, recombinant therapies for gastrointestinal (GI) diseases, announced the completion of site initiation visits...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.